Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome

Stem Cells and Development

Volumn 25, Issue 5, 2016, Pages 395-404

  Moschidou, Dafni ^a   Corcelli, Michelangelo ^a   Hau, Kwan Leong ^a   Ekwalla, Victoria J ^a   Behmoaras, Jacques V ^b   De Coppi, Paolo ^c   David, Anna L ^a   Bou Gharios, George ^d   Cook, H Terence ^b   Pusey, Charles D ^b   Fisk, Nicholas M ^e   Guillot, Pascale V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ASSOCIATED PROTEIN; CD4 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; PODOCIN; RNA; SYNAPTOPODIN; VASCULOTROPIN A; BIOLOGICAL MARKER; COLLAGEN TYPE 4; MEMBRANE PROTEIN; MESSENGER RNA; SIGNAL PEPTIDE;

ALPORT SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CHORIONIC STEM CELL; CONTROLLED STUDY; FEMALE; GLOMERULUS; HUMAN; HUMAN CELL; KIDNEY CORTEX; KIDNEY FIBROSIS; MALE; MOUSE; NEPHRITIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; CELL CULTURE; CELL MOTION; CHORION; COCULTURE; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; FIBROSIS; GENETICS; INFLAMMATION; METABOLISM; MUTATION; NEPHRITIS, HEREDITARY; PATHOLOGY; PHENOTYPE; TRANSPLANTATION;

ANIMALS; BIOMARKERS; CELL DIFFERENTIATION; CELL MOVEMENT; CELLS, CULTURED; CHORION; COCULTURE TECHNIQUES; COLLAGEN TYPE IV; DOWN-REGULATION; FEMALE; FIBROSIS; HUMANS; INFLAMMATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY CORTEX; KIDNEY GLOMERULUS; MALE; MEMBRANE PROTEINS; MICE; MUTATION; NEPHRITIS, HEREDITARY; PHENOTYPE; PODOCYTES; RNA, MESSENGER; STEM CELLS;

EID: 84959340184     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0305     Document Type: Article

References (22)

1. Abrahamson DR, AC Prettyman, B Robert and PL St John. (2003). Laminin-1 reexpression in Alport mouse glomerular basement membranes. Kidney Int 63:826-834.
2. Gross O, L Perin and C Deltas. (2014). Alport syndrome from bench to bedside: the potential of current treatment beyond RAAS blockade and the horizon of future therapies. Nephrol Dial Transplant 29:iv124-iv130.
3. Guillot PV, TH Cook, CD Pusey, NM Fisk, S Harten, J Moss, I Shore and G Bou-Gharios. (2008). Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type I alpha 2-deficient mouse. J Pathol 214:627-636.
4. Sedrakyan S, S Da Sacco, A Milanesi, L Shiri, A Petrosyan, R Varimezova, D Warburton, KV Lemley, RE De Filippo and L Perin. (2012). Injection of amniotic fluid stem cells delays progression of renal fibrosis. J Am Soc Nephrol 23:661-673.
5. Miner JH and JR Sanes. (1996). Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 135:1403-1413.
6. Andrews KL, JL Mudd, C Li and JH Miner. (2002). Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 160:721-730.
7. Prodromidi EI, R Poulsom, R Jeffery, CA Roufosse, PJ Pollard, CD Pusey and HT Cook. (2006). Bone marrow derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport Syndrome. Stem Cells 24:2448-2455.
8. Sugimoto H, TM Mundel, M Sund, L Xie, D Cosgrove and R Kalluri. (2006). Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103:7321-7326.
9. LeBleu V, H Sugimoto, TM Mundel, B Gerami-Naini, E Finan, CA Miller, VH Gattone, 2nd, CF Shield, 3rd, J Folkman and R Kalluri. (2009). Stem cell therapies benefit Alport syndrome. J Am Soc Nephrol 20:2359-2370.
10. Jones GN, D Moschidou, TI Puga-Iglesias, K Kuleszewicz, M Vanleene, SJ Shefelbine, G Bou-Gharios, NM Fisk, AL David, P De Coppi and PV Guillot. (2012). Ontological differences in first compared to third trimester human fetal placental chorionic stem cells. PLoS One 7:e43395.
11. Saleem MA, MJ O'Hare, J Reiser, RJ Coward, CD Inward, T Farren, CY Xing, L Ni, PW Mathieson and P Mundel. (2002). A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 13:630-638.
12. Guillot PV, O Abass, JH Bassett, SJ Shefelbine, G Bou-Gharios, J Chan, H Kurata, GR Williams, J Polak and NM Fisk. (2008). Intrauterine transplantation of human fetal mesenchymal stem cells reduces bone pathology in osteogenesis imperfecta mice. Blood 111:1717-1725.
13. Wong C and I Rogers. (2009). Cell therapy for Alport sydrome. J Am Soc Nephrol 20:2279-2281.
14. Miner JH and JR Sanes. (1994). Collagen IV a3, a4, and a5 chains in rodent basal lamina: sequence, distribution, association with laminins, and developmental switches. J. Cell Biol 127:879-891.
15. Jones GN, D Moschidou, H Abdulrazzak, BS Kalirai, M Vanleene, S Osatis, SJ Shefelbine, NJ Horwood, M Marenzana, et al. (2014). Potential of human fetal chorionic stem cells for the threatment of osteogenesis imperfecta. Stem Cells Dev 23:262-276.
16. Ninichuk V, O Gross, S Segerer, R Hoffmann, E Radomska, A Buchstaller, R Huss, N Akis, D Schlondorff and HJ Anders. (2006). Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 70:121-129.
17. Cosgrove D, DT Meehan, JA Grunkemeyer, JM Kornak, R Sayers, WJ Hunter and GC Samuelson. (1996). Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 10:2981-2992.
18. Gross O, DB Borza, HJ Anders, C Licht, M Weber, S Segerer, R Torra, MC Gubler, L Heidet, et al. (2009). Stem cell therapy for Alport syndrome: the hope beyond the hype. Nephrol Dial Transplant 24:731-734.
19. Lin X, JH Suh, G Go and JF Miner. (2014). Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol 25:687-692.
20. Lasagni L, ML Angelotti, E Ronconi, D Lombardi, S Nardi, A Peired, F Becherucci, B Mazzinghi, A Sisti, et al. (2015). Podocyte regeneration driven by renal progenitors determines glomerular disease remission and can be pharmacologically enhanced. Stem Cell Reports 5:248-263.
21. Tyndall A and V Pistoia. (2009). Mesenchymal stem cells combat sepsis. Nat Med 15:109-118.
22. Ryu M, SR Mulay, N Miosge, O Gross and HJ Anders. (2012). Tumour necrosis factor-α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. J Pathol 226:120-131.